Zonnic Peppermint 1 mg/dosis mundhulespray, opløsning Denmaki - Kidenmaki - Lægemiddelstyrelsen (Danish Medicines Agency)

zonnic peppermint 1 mg/dosis mundhulespray, opløsning

niconovum ab - nicotin - mundhulespray, opløsning - 1 mg/dosis

Zonnic Freshmint 4 mg Mundhulepose Denmaki - Kidenmaki - Lægemiddelstyrelsen (Danish Medicines Agency)

zonnic freshmint 4 mg mundhulepose

niconovum ab - nicotin - mundhulepose - 4 mg

NiQuitin Mint 2,5 mg smeltefilm Denmaki - Kidenmaki - Lægemiddelstyrelsen (Danish Medicines Agency)

niquitin mint 2,5 mg smeltefilm

omega pharma nordic ab - nicotin - smeltefilm - 2,5 mg

Lojuxta Umoja wa Ulaya - Kidenmaki - EMA (European Medicines Agency)

lojuxta

amryt pharmaceuticals dac - lomitapide - hyperkolesterolæmi - lipid modificerende midler - lojuxta er indiceret som et supplement til en low‑fat kost og andre lipid‑lowering lægemidler med eller uden lav density lipoprotein (ldl) aferese hos voksne patienter med homozygot familiær hyperkolesterolæmi (hofh). genetiske bekræftelse af hofh skal indhentes, når det er muligt. andre former for primær hyperlipoproteinaemia og sekundære årsager til hypercholesterolaemia e. nefrotisk syndrom, hypothyroidisme) skal udelukkes,.

Bosulif Umoja wa Ulaya - Kidenmaki - EMA (European Medicines Agency)

bosulif

pfizer europe ma eeig - bosutinib (som monohydrat) - leukæmi, myeloid - antineoplastic agents, protein kinase inhibitors - bosulif er indiceret til behandling af voksne patienter med nyligt diagnosticeret kronisk fase (cp) philadelphia-kromosom-positiv kronisk myelogenous leukæmi (ph+ cml). cp, accelereret fase (ap), og blast fase (bp) ph+ cml, der tidligere er behandlet med en eller flere tyrosin kinase inhibitor(s) [tki(s)], og for hvem imatinib, nilotinib og dasatinib er ikke anset som egnede behandlingsmuligheder.

Tandemact Umoja wa Ulaya - Kidenmaki - EMA (European Medicines Agency)

tandemact

cheplapharm arzneimittel gmbh - pioglitazon, glimepirid - diabetes mellitus, type 2 - narkotika anvendt i diabetes - tandemact er indiceret til behandling af patienter med type-2 diabetes mellitus, som vis intolerance over for metformin eller til hvem metformin er kontraindiceret, og der er allerede behandlet med en kombination af pioglitazon og glimepirid.

Iclusig Umoja wa Ulaya - Kidenmaki - EMA (European Medicines Agency)

iclusig

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. se afsnit 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Nicopatch 14 mg/24 timer depotplastre Denmaki - Kidenmaki - Lægemiddelstyrelsen (Danish Medicines Agency)

nicopatch 14 mg/24 timer depotplastre

pierre fabre medicament - nicotin - depotplastre - 14 mg/24 timer

Nicopatch 21 mg/24 timer depotplastre Denmaki - Kidenmaki - Lægemiddelstyrelsen (Danish Medicines Agency)

nicopatch 21 mg/24 timer depotplastre

pierre fabre medicament - nicotin - depotplastre - 21 mg/24 timer

Nicopatch 7 mg/24 timer depotplastre Denmaki - Kidenmaki - Lægemiddelstyrelsen (Danish Medicines Agency)

nicopatch 7 mg/24 timer depotplastre

pierre fabre medicament - nicotin - depotplastre - 7 mg/24 timer